Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb

Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)


  • The collaboration will evaluate Nektar Therapeutics’ bempegaldesleukin in combination with BMS’ Opdivo (nivolumab) into multiple new registrational trials and the cost of trials will be shared upon the cost-sharing outlined in the terms of the original collaboration agreement
  • The companies have expanded their collaboration for bempeg + nivolumab from three ongoing registrational trials targeted for 1L metastatic melanoma, 1L cisplatin-ineligible metastatic urothelial cancer, 1L metastatic RCC to two additional trials for adjuvant melanoma & in muscle-invasive bladder cancer
  • Additionally, BMS to initiate and fund the P-I/II dose optimization and expansion study for bempeg + nivolumab in combination with axitinib to treat 1L RCC. Bempeg is a CD122-preferential IL-2 pathway agonist targeted for rapid activation and proliferation of cancer-killing immune cells

Click here to read full press release/ article | Ref: BMS | Image: Behance